May 10, 2012, 05.53 PM IST

Cadila Q4 PAT seen down 4% at Rs 171.7 cr

Cadila Healthcare is expected to report a decline of 4% year-on-year in its profit after tax of Rs 171.7 crore for the fourth quarter of FY12, according to CNBC-TV18 poll.

Source: CNBC-TV18

Share . Email . Print . A+

Cadila Q4 PAT seen down 4% at Rs 171.7 cr

Cadila Healthcare is expected to report a decline of 4% year-on-year in its profit after tax of Rs 171.7 crore for the fourth quarter of FY12, according to CNBC-TV18 poll.

Revenues are seen going up by 13.7% to Rs 1,379 crore from Rs 1,213 crore year-on-year.

EBITDA is likely to go up by 18% to Rs 269 crore from Rs 227.8 crore during the same period.

Operating profit margin is expected to be at 19.5% versus 18.8% YoY.

Expectations

Analysts on average expect sales growth due to domestic formulation business especially Biochem which was acquired in Q3FY12; excluding Biochem growth is expected to be lower

In Q3FY12, domestic formulation business (contributed 34%) grew by 18% to Rs 469 crore due to acquisition of Biochem. Excluding Biochem growth was 12% YoY

Watch out for Consumer business (under Zydus Wellness), which recorded a significant slowdown in 9MFY12 (0% growth YoY for 9MFY12 and 12% YoY decline in Q3FY12 due to rising competition.

Consumer business (contributed 6%) de-grew by 12% due to increase in competitive pressures from MNCs on key brands Sugar Free, EverYuth and Nutralite

US growth is expected to be flat QoQ

Do not expect a one of income from Nycomed JV like the last Q where there was a one off sale of Rs 15 crore